Intra-Cellular Therapies (ITCI) News Today

Vanguard Group Inc. grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,225,981 shares of the biopharmaceutical compan

Russell Investments Group Ltd. lifted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 232.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,845

Clearbridge Investments LLC raised its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 12.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,744,551 shares of the biopharmac

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and ten have assigned a

Sei Investments Co. raised its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 9.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,311 shares of the biopharmaceutical c

Lord Abbett & CO. LLC lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 38.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 472,687 shares of the biopharmaceutical company's stock after s

SageView Advisory Group LLC bought a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,196 shares of the biopharmaceutical company's stock, valued

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totalling 4,140,000 shares, a growth of 11.0% from the June 15th total of 3,730,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is currently 3.2 days.

TimesSquare Capital Management LLC trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 22.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 383,211 shares of the biopharmaceutical company's stock after selling 113,139

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2027 earnings estimates for Intra-Cellular Therapies in a research report issued to clients and investors on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now expects that t

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 3,730,000 shares, a decline of 6.8% from the May 31st total of 4,000,000 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is currently 3.6 days.

Wasatch Advisors LP increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,854,747 shares of the biopharmac

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and ten h

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57, for a total value of $337,193.34. Following the sale, the director now owns 116,600 shares in the company, valued at $8,811,462. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

UBS Group reiterated a "neutral" rating and issued a $83.00 target price (down from $85.00) on shares of Intra-Cellular Therapies in a report on Tuesday.

Vanguard Group Inc. boosted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 6.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 9,094,302 shares of the biopharmaceutical company's stock after buying an additio

Mizuho boosted their price objective on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday.

Wellington Management Group LLP lessened its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,763,475 shares of the biopharmaceutical company's stock after selling

Canaccord Genuity Group boosted their price objective on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a "buy" rating in a research note on Thursday.

Needham & Company LLC increased their price objective on shares of Intra-Cellular Therapies from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Tuesday.

Intra-Cellular Therapies (NASDAQ:ITCI) Shares Gap Up to $68.87

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 4,000,000 shares, a decline of 12.1% from the May 15th total of 4,550,000 shares. Based on an average trading volume of 928,400 shares, the short-interest ratio is presently 4.3 days.

Perceptive Advisors LLC bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 108,000 shares of the biopharmaceutical company's stock, valued at appr

Parkman Healthcare Partners LLC acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 186,272 shares of the biopharmaceutical company's stock

Avidity Partners Management LP decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 11.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 710,000 shares of the biopharmaceutical company's stock after selling 91,100 s

Wasatch Advisors LP trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,627,308 shares of the biopharmaceutical company's stock after sellin

Schroder Investment Management Group increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 779,823 shares of

Sectoral Asset Management Inc. cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 94.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,420 shares of the biopharmaceutical company's stock after selling 116,

TD Asset Management Inc acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 72,648 shares of the biopharmaceutical company's stock, valued at

UBS Group AG grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 205.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,762 shares of the biopharmaceutical company'

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have g

Eagle Asset Management Inc. boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 435,718 shares of the biopharmaceutical company

Norges Bank purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,197,203 shares of the biopharmaceutical company's stock, valued at approximately $85,744,000. Norges

Clearbridge Investments LLC lifted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,553,135 shares of the biopharmaceutical company's stoc